Background: Clinical decisions are made based on Cochrane systematic reviews (CSRs), but 23 implementation of results of evidence syntheses such as CSRs is problematic if the evidence 24 is not prepared consistently. All systematic reviews should assess risk of bias (RoB) had 'other bias' domain in the RoB tool, and they included a total of 7811 RCTs. In the RoB 33 table of 337 CSRs for at least one of the included trials it was indicated that no other bias was 34 found and supporting explanations were inconsistently judged as low, unclear or high RoB. In 35 the 524 CSRs that described various sources of other bias there were 5762 individual types of 36 explanations which we categorized into 31 groups. The judgments of the same supporting 37 explanations were highly inconsistent. Furthermore, we found numerous other inconsistencies 38 in reporting of sources of other bias in CSRs. 
Introduction 50
Assessment of the risk of bias (RoB) in included studies is an integral part of preparing 51
Cochrane systematic reviews (CSRs). Bias is any systematic error that can negatively affect 52 estimated effects of interventions and lead authors to wrong conclusions about efficacy and 53 safety of analyzed interventions [1] . 54
CSRs use Cochrane's RoB tool, whose aim is to enable better appraisal of evidence and 55 ultimately lead to better healthcare [2]. Cochrane's standard RoB tool has seven domains, of 56 which first six refer to specific potential biases while the seventh domain is called 'other 57 bias', which is used for bias occurring due to any additional problems that were not covered 58 elsewhere in the first six domains [3] . 59
The Cochrane Handbook provides some examples of other potential threats to validity, such 60 as design-specific risk of bias in non-randomized trials, baseline imbalance between groups of 61 participants, blocked randomization in trials that are not blinded, differential diagnostic 62 activity, study changes due to interim results, deviations from the study protocol, giving 63 intervention before randomization, inappropriate administration of an intervention or having 64 co-intervention(s), contamination due to drug pooling among participants, insufficient 65 delivery of intervention, inappropriate inclusion criteria, using instruments that are not 66 sensitive for specific outcomes, selective reporting of subgroups and fraud [3] . 67
This list of potential other sources of bias mentioned in the Cochrane Handbook is limited, 68
and it would therefore be useful to explore potential additional sources of 'other bias'. By 69 consulting a more comprehensive list of potential other biases, systematic review might 70 recognize certain problems in included studies that might not otherwise consider a potential 71 source of bias. 72
The aim of this study was to analyze the scoring and support for judgment of the category 73 'other bias' in a large number of interventional CSRs of randomized controlled trials (RCTs) 74 published in the Cochrane Database of Systematic Reviews (CDSR). 75
Methods 76
We conducted a retrospective analysis of published CSRs. 77
78

Inclusion and exclusion criteria 79
We retrieved CSRs of RCTs about interventions published from July 2015to June 2016 (N = 80 955) by using Advanced search in The Cochrane Library. Diagnostic CSRs, empty CSRs, 81 overviews of systematic reviews and CSRs withdrawn in this period were excluded. CSRs 82 that included both RCTs and non-randomized trials were included, but 
Sources of other bias 148
In the 524 analyzed CSRs that described various sources of other bias, there were 5762 149 different supporting explanations for judgments of other bias that we categorized into 31 150 categories. In 535 trials it was indicated only that it was not possible to assess other bias. For 151 24 (4%) of those 535 trials it was not indicated why this was not possible, while the most 152 common reasons for not being able to assess other bias were that there were 'insufficient 153 information' (N=392, 73%), the trial was published as a conference abstract only (N=78, 154 15%) and that the trial was published in foreign language so there were issues with translation 155 (N=11, 2%). Cochrane authors were not consistent in judging this type of supporting 156 explanation; for 11 (2%) trials it was judged as high RoB, for 520 (94%) as unclear RoB and 157 for 4 (0.7%) as low RoB. 158 There were 236 trials for which Cochrane authors simply wrote that issues related to other 159 bias were not described or unclear. This type of supporting explanation was also 160 inconsistently judged by the Cochrane authors; 7 (3%) judged it as low RoB and 229 (97%) as 161 unclear RoB. 162
The remaining 4991 explanations for judgments of other bias were divided into 29 categories 163 that are shown in Table 1 . The most frequently used categories of explanations for other bias 164 were related to baseline characteristics of participants, funding of a trial, reporting, sample 165 size and conflict of interest (Table 2) . Cochrane authors used the domain for other bias to 166 indicate positive, negative and unclear aspects of a trial. For example, three most common 167 types of explanations in the category related to baseline characteristic of participants indicated 168 that either baseline characteristics were similar, or that there was imbalance in baseline 169 characteristics, or that there was insufficient information about it. Among 4991 explanations, 170
we were unable to categorize 85 of them because they were uninformative, including 171 explanations such as 'Adequate' or 'N/A' or 'Other risk of bias was possible'. Finally, there 172
were 112 explanations that were used only once or twice in RoB tables we analyzed so we 173 categorized that group as 'Other explanations'. 174
175
Partial studies included in the primary analysis 176
We found 34 CSRs with specific partial data regarding other bias. We divided them into four 177 distinct groups: first group with 28 CSRs that had judgments for 'other bias', but not all had 178 accompanying comments, second group with 4 CSRs where only one included RCT did not 179 have the 'other bias' domain, third group with one CSR with included RCT without 'other 180 bias' domain and included RCT with only judgment without comment, and fourth group with 181 one CSR where RoB table was completely missing for 6 included RCTs. Some CSRs had 182 additional non-standard RoB domains, separately or in addition to the 'other bias' domain. 183
Categories of additional non-standard RoB domains in CSRs are shown in Table 3 We found 9 CSRs that consistently did not use supporting explanations for judgment or they 226 used non-standard judgments. In 5 CSRs authors used judgments low, high or unclear RoB, 227 but without comments as support for judgment. In one CSR all trials were marked with 228 unclear risk of other bias without any comment as support for judgment. In four CSRs all 229 trials were marked with low risk of other bias without any comment as support for judgment. 230
We also found 4 CSRs that did not have judgments low-high-unclear, but different kinds of 231 judgments. One CSR had judgments yes/no without supporting comments; two CSRs had 232 judgments yes, no or unclear, with supporting comments and there was one CSR with 233 judgments A-adequate and B-unclear. 234
Discussion 236
In this study we analyzed 768 Cochrane systematic reviews, with 11369 included trials. We 237 found that Cochrane authors used numerous different categories of sources of other bias and 238 that they were not judging them consistently. We categorized different types of supporting 239 explanations into 31 categories, and we found numerous other inconsistencies in reporting of 240 sources of other bias in CSRs. Findings of this study are disconcerting because consistency in 241 secondary research is very important to ensure comparability of studies. 242
Insufficient and unclear reporting of the 'other bias' domain was very common in the CSRs 243 we analyzed. Among the most common support for judgment were comments that we 244 categorized as 'not described/unclear', which is puzzling because 'other bias' domain is not 245 specific like the other six domains of the RoB tool, and it is therefore difficult to fathom what 246 it means that other bias was not described or that it was unclear. If the authors did not find 247 sources of other bias, or if they thought that they could not assess other bias because of 248 brevity of report or language issues, they should have stated that. Likewise, for some trials the 249 only supporting explanation was that other bias was 'Adequate'. Without any further 250 explanations, readers cannot know what exactly the Cochrane authors found to be adequate in 251 terms of other potential sources of bias. Many systematic reviews had a high number of 252 included studies, and therefore some comments were repeated multiple times in the same 253 systematic review. 254
The most commonly used specific category of other bias referred to baseline characteristics of 255 participants. In RCTs randomization should ensure allocation of participants into groups that 256 differ only in intervention they received. Randomization should ensure that characteristics of 257 participants that may influence the outcome will be distributed equally across trial arms so 258 that any difference in outcomes can be assumed to be a consequence of intervention 259 [4] .Baseline imbalances between the groups may indicate that there was something wrong 260 with the randomization process, or that they might be due to chance [5] . Severe baseline 261 imbalances can occur because of deliberate actions of trialists if they aim to intentionally 262 subvert the randomization process [6]or due to unintentional errors. 263
Chance imbalances should not be considered a source of bias, but it may be difficult to 264 distinguish whether baseline imbalances are caused by chance or intentional actions. If there 265 are multiple studies included in a meta-analysis, it could be expected that chance imbalances 266 will act in opposite directions. But the problem may occur if there is a pattern of imbalances 267 across several trials that may favor one intervention over another, suggesting imbalance due 268 to bias and not due to chance [7] . Cochrane is now developing a second generation of the RoB 269 tool, titled RoB 2.0, and one of the signaling questions in the RoB domain about 270 randomization process asks "Were there baseline imbalances that suggest a problem with the 271 randomization process" [7] . The fact that so many Cochrane authors used comments about 272 baseline imbalance as a domain of other bias, and not in the RoB domain about random 273 sequence generation (selection bias) indicate that many Cochrane authors consider that this 274 aspect should be emphasized separately from the selection bias domain. 275
The second most commonly used category of supporting explanations was related to funding 276 of a trial, and comments about conflicts of interest were the fifth most common category. This 277 is in direct contrast with the recommendations from the Cochrane Handbook, where it is 278 acknowledged that information about vested interests should be collected and presented when 279 relevant, but not in the RoB The third most frequent category of supporting explanations for other bias was related to poor 297 reporting, where Cochrane authors indicated that relevant information were missing or were 298 inadequately reported. Poor reporting hinders transparency, as it allows authors to avoid 299 attention to weak aspects of their studies. For this reason reporting guidelines should be used 300 [12] . 301
Comments about sample size were the fourth most common category either in a sense that the 302 trial did or did not report sample size calculation, or that sample size was "small" without any 303
further explanation of what the Cochrane authors considered to be a small sample. There were 304 21 trials for which Cochrane authors wrote that there were fewer than 50 participants in each 305 arm. It is unclear where this cut-off is coming from, as there is no such guidance in the 306
Cochrane Handbook in the chapter about risk of bias. On the contrary, chapter 8.15.2. of the 307 Cochrane Handbook specifically warns that "sample size or use of a sample size (or power) 308 calculation" are examples of quality indicators that "should not be assessed within this 309 domain" [8] . 310
The Cochrane Handbook also warns that authors should avoid double-counting, by not 311 including potential sources of bias in the 'other bias' domain if they can be more appropriately 312 covered by other domains in the tool [8] . As can be seen by our study, Cochrane authors 313 sometimes do double-counting because there were categories of comments supporting 314 judgments that could have been addressed in the first six domains. 315
As we have shown, most of Cochrane authors decided to use the other bias domain to describe 316 potential additional biases that were not covered in the first six domains of the RoB tool. In 317 the proposed RoB tool 2.0 there is no 'other bias' domain [7] . The proposed RoB tool is much 318 more complex, compared to the current version of the RoB tool, and many items that were 319 specifically emphasized by Cochrane authors in the other bias domain, as shown in our study, 320 are addressed in the RoB 2.0 tool. However, there are still potential biases from other sources 321 that the RoB 2.0 may neglect by omitting the RoB domain, such as biases specific to certain 322 topics, and those that were not recognized by the RoB 2.0 tool in advance. 323
We have already conducted a similar analysis of Cochrane RoB domain related to attrition 324 bias, and we found that judgments and supports for judgments in that domain were extremely 325 inconsistent in CSRs (unpublished data). This analysis related to sources of other bias in 326
CSRs contributes to the perception that Cochrane RoB tool is inconsistently used among 327
Cochrane authors. The authors do not necessarily follow guidance from the Cochrane 328
Handbook. In the support for judgment they mention issues that the Cochrane Handbook 329 explicitly warns against. Various comments that serve as supports for judgments were 330 inconsistently judged across CSRs and trials included in CSRs. Cochrane authors also use 331 inconsistent terminology to describe the same concepts. Increasing complexity of the RoB 332 tool, as proposed in the RoB tool 2.0 will likely only increase this problem of insufficient 333 consistency in RoB appraisal and worsen this problem of insufficient comparability of 334 judgments of RoB across CSRs. 335 Furthermore, our study indicated that Cochrane authors extensively use the available option to 336 customize the RoB 
